Exacerbation protection demonstrated in Trial 2 (53% reduction vs placebo; NUCALA+SOC 0.83/year, placebo+SOC 1.74/year, P<0.001).1
Protect your patients from exacerbations
Proven protection from exacerbations
Trial 2 (32 weeks)1
Primary endpoint at Week 32.
SOC=standard of care.
Trend of greater reduction in exacerbations seen at higher blood eosinophil levels
Post hoc analysis: Trial 22
Demonstrated protection in Trial 21
NUCALA+SOC: 0.08/year,
placebo+SOC: 0.20/year; P=0.02
Secondary endpoint at Week 32.
ED=emergency department
ED=emergency department
Real-world study: Interim analysis at 12 months, secondary objective4
Results are descriptive. 12 months post-exposure NUCALA: 0.27/year vs 12 months pre-exposure: 1.14/year; rate ratio 0.23 (95% CI: 0.18, 0.30).
Real-world study limitations: Prespecified interim analysis of a 2-year, single-arm, prospective, observational cohort study; may not reflect results from the final dataset.
Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.
ED=emergency department.
Results are descriptive.
Mean baseline blood eosinophil levels2
- current nasal polyps, 440 cells/μL
- no nasal polyps, 290 cells/μL
- total patient population, 330 cells/μL
Trial 2/MUSCA post hoc meta-analysis study design evaluated annual rate of exacerbations in select subgroups of patients with severe eosinophilic asthma.5
Trial 2/MUSCA Post-hoc meta-analysis: subgroup analysis5
Results are descriptive.
Of the total population (n=936), 907 patients had analyzable data.5
Positive atopic status defined as a RAST score ≥3 (ie, High or Very High allergic response) on at least 1 of 5 allergens: house dust mite, dog dander, cat dander, Alternaria, and cockroach.5
RAST=radioallergosorbent test.
Trial 2/MUSCA post hoc meta-analysis study design2 evaluated annual rate of exacerbations in select subgroups of patients with severe eosinophilic asthma.
